p24-VLP vaccine

fragment of an HIV protein known as p24 presented on the surface of a newly emergent vaccine carrer known as virus-like particle

Also Known As:

HIV major core protein p24-virus like particle vaccine; p24-VLP

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Colebunders, Robert: 1 article (05/2002)
2.	Coutinho, Roel A: 1 article (05/2002)
3.	Fisher, Martin: 1 article (05/2002)
4.	Langendam, Miranda W: 1 article (05/2002)
5.	Lindenburg, Catharina E A: 1 article (05/2002)
6.	Miedema, Frank: 1 article (05/2002)
7.	Stolte, Ineke: 1 article (05/2002)
8.	Weber, Jonathan N: 1 article (05/2002)
9.	Williams, Ian G: 1 article (05/2002)
10.	006 Study Group: 1 article (10/2001)

1.	Acquired Immunodeficiency Syndrome (AIDS) 05/22/2002 - "Long-term effects of therapeutic vaccination of human immunodeficiency virus (HIV)-1-infected subjects with HIV-1 p17/p24:Ty virus-like particles (p24-VLP) on progression to AIDS, death, a CD4 cell count <or=200 cells/mm(3) and CD4 cell count decline were studied in a multicenter cohort study of 56 individuals who participated in a phase II double-blind placebo-controlled trial with p24-VLP in 1993. "
2.	HIV Infections (HIV Infection) 10/01/2001 - "Therapeutic vaccination with p24-VLP does not affect CD4 cell decline in patients with advanced HIV infection."